William Blair upgraded Akari Therapeutics (NASDAQ:AKTX) to “outperform” from “market perform” after the company announced that, following its end-of-Phase-2 meeting with the FDA, it is advancing Coversin for the treatment of paroxysmal nocturnal hemoglobinuria into two Phase 3 trials - ASSET and CAPSTONE - both of which are set to begin during the first quarter of 2018.Read More
Leerink initiated coverage of Dova Pharmaceuticals (NASDAQ:DOVA) with a “market perform” rating and a $24 price target. The stock closed at $22.75 on July 21.Read More
QLT (NASDAQ:QLTI; TSX:QLT) and Aegerion Pharmaceuticals (NASDAQ:AEGR) have entered into a definitive merger agreement, with the resulting company to be renamed, Novelion Therapeutics.
Under the accord, each outstanding share of Aegerion common stock will be exchanged for 1.0256 shares of QLT common stock.Read More
Oramed Pharmaceuticals (NASDAQ:ORMP) has reported positive top-line results from its Phase 2b study, designed to evaluate the safety and efficacy of its oral insulin capsule, ORMD-0801, in patients with Type 2 diabetes.
The study’s primary objective, which is a significant reduction of weighted mean nighttime glucose, was successfully achieved.Read More
H.C. Wainwright has initiated coverage of Paratek Pharmaceuticals (NASDAQ:PRTK) with a “buy” rating and $32 price target. The stock closed at $15.51 on Friday.
Paratek’s lead drug, omadacycline, is a broad-spectrum antibiotic with potent coverage of common bacterial pathogens such as MRSA in both acute bacterial skin and skin structure infection (ABSSSI) and community-acquired bacterial pneumonia (CABP); multi-drug resistant Streptococcus pneumoniae (MDRSP) in CABP; and extended spectrum beta-lactamase-producing Enterobacteriaceae in urinary tract infections (UTI).Read More
Dipexium Pharmaceuticals’ (NASDAQ:DPRX) OneStep-1 and OneStep-2 pivotal Phase 3 clinical trials have reached the 75% enrollment milestone in total, with each study having enrolled nearly the same number of patients.
OneStep-1 and OneStep-2 are identical Phase 3 trials, with 180 patients per clinical trial. They are being conducted under a SPA with the FDA for evaluation of Locilex for the treatment of patients with mild infections of diabetic foot ulcers.Read More